Ye Xuxiao, Shami Jessica J P, Yan Vincent K C, Kang Wei, Blais Joseph E, Zhao Jiaxi, Lau Wallis C Y, Wei Li, Wong Ian C K, Chan Esther W
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region.
Laboratory of Data Discovery for Health, Hong Kong Special Administrative Region.
Am Heart J Plus. 2021 Jun 16;4:100020. doi: 10.1016/j.ahjo.2021.100020. eCollection 2021 Apr.
P2Y12 inhibitors are an important component of dual antiplatelet therapy. Yet, their accessibility and affordability across countries stratified by income levels have not been studied.
Sales data were retrieved from the IQVIA Multinational Integrated Data Analysis System for the description of P2Y12 inhibitors global sales. Countries were stratified into 38 high-income countries and 27 middle-income countries.
Global sales of P2Y12 inhibitors increased from 0.80 SU per year per person in 2008 to 1.79 in 2018. Growth in sales of P2Y12 inhibitors was greater in middle-income countries compared to high-income countries. Clopidogrel had the highest sales volume in both high-income and middle-income countries from 2008 to 2018, while ticagrelor sales volume increased mainly in high-income countries.
Despite current guideline recommendations favoring ticagrelor and prasugrel for the prevention of atherothrombotic complications in patients with an acute coronary syndrome, clopidogrel retained the highest sales volume among the P2Y12 inhibitors from 2008 to 2018.
P2Y12抑制剂是双联抗血小板治疗的重要组成部分。然而，按收入水平分层的各国对其可及性和可负担性尚未进行研究。
从艾昆纬跨国综合数据分析系统检索销售数据，以描述P2Y12抑制剂的全球销售情况。国家被分为38个高收入国家和27个中等收入国家。
P2Y12抑制剂的全球销售额从2008年的每人每年0.80销售单位增加到2018年的1.79。与高收入国家相比，中等收入国家P2Y12抑制剂的销售额增长更大。2008年至2018年，氯吡格雷在高收入和中等收入国家的销量均最高，而替格瑞洛的销量主要在高收入国家增加。
尽管目前的指南推荐替格瑞洛和普拉格雷用于预防急性冠状动脉综合征患者的动脉粥样硬化血栓形成并发症，但2008年至2018年期间，氯吡格雷在P2Y12抑制剂中的销量仍最高。
